Acinetobacter baumannii has emerged as a medically important pathogen because of the
increasing number of infections produced by this organism over the preceding three …

The optimal treatment for multidrug-resistant A. baumannii nosocomial infections has not
been established. Carbapenems are the mainstay of treatment in susceptible isolates …

Colistin resistance is rare in Acinetobacter baumannii, and little is known about its
mechanism. We investigated the role of PmrCAB in this trait, using (i) resistant and …

The purpose of this investigation was to compare the efficacy of colistin-based therapies in
extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A …

Multidrug-resistant Acinetobacter baumannii (MDR-AB) infections are difficult to treat owing
to the extremely limited armamentarium. The present review reports all available treatment …

The increase of multiresistance in bacteria and the shortage of new antibiotics in the market
is becoming a major public health concern. The World Health Organization (WHO) has …

Of 112 non-repetitive clinical isolates of Acinetobacter baumannii–Acinetobacter
calcoaceticus complex, 80% were resistant to a variety of structurally unrelated …

Acinetobacter baumannii causes pneumonias, bacteremias, and skin and soft tissue
infections, primarily in the hospitalized setting. The incidence of infections caused by A …

The global emergence of multidrug resistant Acinetobacter baumannii has reduced the
number of clinically available antibiotics that retain activity against this pathogen. For this …

The treatment of infections caused by Acinetobacter baumannii has become increasingly
complicated due to the emergence of highly resistant strains. In the present study we …